Skip to main content

Research Repository

Advanced Search

Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease ß Secretase, BACE1

Mycroft-West, Courtney J.; Devlin, Anthony J.; Cooper, Lynsay C.; Guimond, Scott E.; Procter, Patricia; Guerrini, Marco; Miller, Gavin; Fernig, David G.; Yates, Edwin A.; Lima, Marcelo A.; Skidmore, Mark A.

Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease ß Secretase, BACE1 Thumbnail


Courtney J. Mycroft-West

Anthony J. Devlin

Lynsay C. Cooper

Marco Guerrini

David G. Fernig

Edwin A. Yates


Only palliative therapeutic options exist for the treatment of Alzheimer’s Disease; no new successful drug candidates have been developed in over 15 years. The widely used clinical anticoagulant heparin has been reported to exert beneficial effects through multiple pathophysiological pathways involved in the aetiology of Alzheimer’s Disease, for example, amyloid peptide production and clearance, tau phosphorylation, inflammation and oxidative stress. Despite the therapeutic potential of heparin as a multi-target drug for Alzheimer’s disease, the repurposing of pharmaceutical heparin is proscribed owing to the potent anticoagulant activity of this drug. Here, a heterogenous non-anticoagulant glycosaminoglycan extract, obtained from the shrimp Litopenaeus vannamei, was found to inhibit the key neuronal ß-secretase, BACE1, displaying a more favorable therapeutic ratio compared to pharmaceutical heparin when anticoagulant activity is considered.

Journal Article Type Article
Acceptance Date Mar 26, 2021
Online Publication Date Apr 3, 2021
Publication Date Apr 3, 2021
Journal Marine Drugs
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 19
Issue 4
Pages 203 -203
Keywords Alzheimer’s disease, amyloid-ß, BACE1, ß-secretase, glycosaminoglycan, chondroitin sulfate, heparin, heparan sulphate, Litopenaeus vannamei
Publisher URL


You might also like

Downloadable Citations